SG11202008921YA - Micro-rna and obesity - Google Patents

Micro-rna and obesity

Info

Publication number
SG11202008921YA
SG11202008921YA SG11202008921YA SG11202008921YA SG11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA SG 11202008921Y A SG11202008921Y A SG 11202008921YA
Authority
SG
Singapore
Prior art keywords
obesity
rna
micro
Prior art date
Application number
SG11202008921YA
Other languages
English (en)
Inventor
Pier Paulo Pandolfi
Riccardo Panella
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of SG11202008921YA publication Critical patent/SG11202008921YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202008921YA 2018-03-14 2019-03-14 Micro-rna and obesity SG11202008921YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642934P 2018-03-14 2018-03-14
PCT/US2019/022350 WO2019178410A1 (fr) 2018-03-14 2019-03-14 Micro-arn et obésité

Publications (1)

Publication Number Publication Date
SG11202008921YA true SG11202008921YA (en) 2020-10-29

Family

ID=67908026

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202008925VA SG11202008925VA (en) 2018-03-14 2019-03-14 Inhibitors of micro-rna 22
SG11202008921YA SG11202008921YA (en) 2018-03-14 2019-03-14 Micro-rna and obesity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202008925VA SG11202008925VA (en) 2018-03-14 2019-03-14 Inhibitors of micro-rna 22

Country Status (11)

Country Link
US (2) US11499152B2 (fr)
EP (2) EP3765610A4 (fr)
JP (2) JP7318166B2 (fr)
KR (2) KR20200132920A (fr)
CN (2) CN111918968B (fr)
AU (2) AU2019234917A1 (fr)
BR (2) BR112020018705A2 (fr)
CA (2) CA3093844A1 (fr)
RU (2) RU2020131372A (fr)
SG (2) SG11202008925VA (fr)
WO (2) WO2019178411A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7318166B2 (ja) 2018-03-14 2023-08-01 ベス イスラエル デアコネス メディカル センター マイクロｒｎａ２２の阻害剤
CN110609142A (zh) * 2019-10-09 2019-12-24 广州医科大学附属第二医院 一种检测外周血fto蛋白与自身调控元件结合能力的方法与应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117304258B (zh) * 2022-09-09 2024-09-24 湖南大学 一种多肽的用途
EP4353823A1 (fr) * 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibiteurs de micro-arn 22

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
JP2002516256A (ja) 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
WO2003093449A2 (fr) 2002-05-06 2003-11-13 Nucleonics, Inc. Procedes d'administration d'acides nucleiques
ES2503765T3 (es) * 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CA2903764A1 (fr) * 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micro-arn regulant la proliferation et la differenciation des cellules musculaires
CA3024953A1 (fr) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Composition pharmaceutique comprenant des oligonucleotides antisens anti-microarn
AU2013254923A1 (en) * 2006-04-03 2013-11-28 Santaris Pharma A/S Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide
EA019939B1 (ru) * 2007-10-04 2014-07-30 Сантарис Фарма А/С МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
US8962253B2 (en) * 2009-04-13 2015-02-24 Somagenics Inc. Methods and compositions for detection of small RNAs
AU2010258875A1 (en) * 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
UY33807A (es) * 2010-12-17 2012-07-31 Sanofi Sa miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
EP3159410A2 (fr) 2011-04-12 2017-04-26 Beth Israel Deaconess Medical Center, Inc. Inhibiteurs de micro-arn et leurs utilisations dans des maladies
US20150031574A1 (en) * 2012-02-23 2015-01-29 Sumitomo Bakelite Co., Ltd. Method for classification of test body fluid sample
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
WO2013181613A1 (fr) 2012-05-31 2013-12-05 Research Development Foundation Miarn pour le diagnostic et le traitement d'une maladie auto-immune et inflammatoire
WO2013192576A2 (fr) * 2012-06-21 2013-12-27 Miragen Therapeutics Inhibiteurs à base d'oligonucléotides comprenant un motif d'acide nucléique bloqué
US9822358B2 (en) 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
US10358643B2 (en) * 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
EP3253871A1 (fr) 2015-02-04 2017-12-13 Bristol-Myers Squibb Company Oligonucléotides lna à flancs alternés
EP3270984A4 (fr) * 2015-03-16 2019-04-17 Duncan Ross Procédé de traitement comprenant des vésicules logées dans une membrane
US20190127736A1 (en) * 2016-04-29 2019-05-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN107432933A (zh) * 2017-07-13 2017-12-05 中南大学湘雅三医院 miR‑22作为靶位点在制备膀胱癌的化疗增敏治疗药物中的应用
WO2019053235A1 (fr) * 2017-09-15 2019-03-21 Genfit Diagnostic non invasif de maladies du foie gras non alcooliques, de la stéatohépatite non alcoolique et/ou de la fibrose hépatique
JP7318166B2 (ja) 2018-03-14 2023-08-01 ベス イスラエル デアコネス メディカル センター マイクロｒｎａ２２の阻害剤
WO2019217907A1 (fr) * 2018-05-11 2019-11-14 The Regents Of The University Of California Méthodes et compositions pour le traitement du cancer et de maladies hepatiques et métaboliques

Also Published As

Publication number Publication date
CN111918968B (zh) 2023-11-24
RU2020131372A (ru) 2022-04-14
KR20200132920A (ko) 2020-11-25
AU2019234917A1 (en) 2020-10-01
CN111918968A (zh) 2020-11-10
EP3765619A4 (fr) 2021-12-08
KR20200131287A (ko) 2020-11-23
CN112119159A (zh) 2020-12-22
JP7318166B2 (ja) 2023-08-01
US11499152B2 (en) 2022-11-15
US20210017520A1 (en) 2021-01-21
EP3765619B1 (fr) 2024-10-09
RU2020132725A (ru) 2022-04-15
CA3093572A1 (fr) 2019-09-19
EP3765610A4 (fr) 2022-01-19
CA3093844A1 (fr) 2019-09-19
BR112020018752A2 (pt) 2021-01-05
EP3765619A1 (fr) 2021-01-20
JP2021518159A (ja) 2021-08-02
EP3765610A1 (fr) 2021-01-20
WO2019178411A1 (fr) 2019-09-19
US11753639B2 (en) 2023-09-12
WO2019178410A1 (fr) 2019-09-19
JP2021518841A (ja) 2021-08-05
AU2019234916A1 (en) 2020-10-15
US20210017521A1 (en) 2021-01-21
BR112020018705A2 (pt) 2021-01-05
SG11202008925VA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
IL275737A (en) Variant antibodies against TIGIT
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
SG11202008921YA (en) Micro-rna and obesity
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL281297A (en) Anti-NPR1 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL276807A (en) Modified 2 plyss lysine and its uses
IL278832A (en) Improved molecules that bind 41GP
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL283926A (en) Antibodies against alpha-synuclein and their uses
GB201812561D0 (en) Biomarkers and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
IL283890A (en) Anti-periostin antibodies and their uses
IL275211A (en) Fast and flexible segment chains - division
GB201805262D0 (en) Flexible pipebody and method
IL287503A (en) Thio-semicarbazide compounds and their use